Cadrenal Therapeutics, Inc. (CVKD) has disclosed a new risk, in the Innovation / R&D category.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cadrenal Therapeutics, Inc. faces uncertainty because its future success hinges on the FDA’s review of its Phase 3 trial protocol for CAD-1005 in HIT. Until it receives the official March 26, 2026 EOP2 meeting minutes and any subsequent protocol comments, the company remains exposed to potential delays or costly additional studies.
The absence of finalized FDA feedback means the apparent registrational path could still shift in scope, design, or endpoints. If the FDA mandates further trials or data, Cadrenal Therapeutics, Inc. may encounter extended timelines, higher development expenses, and a delayed path to potential commercialization.
Overall, Wall Street has a Moderate Buy consensus rating on CVKD stock based on 1 Buy.
To learn more about Cadrenal Therapeutics, Inc.’s risk factors, click here.